Artificial Intelligence's First Display of Power
"Great, approved. Keep it up, do a good job."
Wei Kang closed the document, quickly signed it, and then handed it to Tang Que across from him.
However, after thinking for a moment, he added a few more words.
"By the way, the company's Artificial Intelligence research and development has made great progress recently. You can try using it for drug screening or to construct gene expression vectors."
Tang Que nodded, then left silently.
He quickly broke down the tasks and then assigned them.
A small team of two or three people was formed and assigned their own tasks.
The entire Biology Laboratory was like a gear at full power, running with tremendous force.
They need to repeat two known routes to replicate their competitor's drug.
Tang Que could sense that this was not an easy task, but a test.
If they get stuck at this step, they won't be able to continue and develop their Three Purities medicine.
The reason is obvious: we can use the ideas of our competitors, but the drug molecules and viral vectors cannot be the same, so as not to infringe on their patent protection.
Otherwise, even if corresponding Gene Therapy drugs are developed, they will still be constrained by intellectual property rights and will not be able to achieve true domestic production of Chinese medicine.
To circumvent patent barriers and find our own drugs, we clearly need a deep understanding of virological vectors and Genomics. This is part of basic scientific research and requires solid accumulation; it's not something that can be achieved immediately by trying to take shortcuts.
Behind this often lies decades of research accumulation from interdisciplinary fields such as biology, virology, and molecular evolution.
His expression was solemn; he was prepared for a protracted battle.
However, a week later, Tang Que sat in his office, staring at the two people in front of him, and blurted out in disbelief.
"What? It's done?"
He stared at it for a full ten seconds before frowning and asking, "Are you sure?"
Across from him stood the refined and handsome Jiang Kai, a fellow alumnus of Chen Yiqing, Harvard PhD in biology. He returned to China at the same time as Xiang Gaofei and had been working at the Three Purities Biology Laboratory for more than half a year. Due to his outstanding abilities, he became a research and development team leader.
Jiang Kai said slowly and deliberately, "Yes, the analysis of Novartis's Z drug is almost complete, the AVV9 Adenovirus Vector has been constructed, the data display on the computer is perfect, and the Cell Experiment are 100% consistent."
Tang Que asked with some surprise and doubt, "So fast?"
"This involved using the company's new AI software to construct the viral vector and study its interaction with its receptor, which resulted in exceptionally rapid progress. Once the samples are produced, we will conduct Animal Experiment as soon as possible to further verify the effectiveness."
Standing next to him was another man, a round-faced man of medium build, who quickly nodded in agreement. "Indeed, our small molecule drug development is also progressing exceptionally smoothly. After analyzing the drug targets, we quickly replicated the relevant drugs and improved mRNA cleavage. Animal Experiment are also underway."
Tang Que stroked the stubble on his chin and fell into deep thought.
After a while, he waved his hand, signaling the two people opposite him to leave.
He then focused intently on examining the relevant data and information.
After a long while, he finally let out a long sigh of relief, "It's really done. This speed far exceeded my expectations. I thought it would take at least two or three months to make any progress."
"It seems this newly launched AI software is quite useful." He opened the software called AICell on his desktop and logged in.
The software is very powerful. It not only has a complete human genome database, but also allows you to design genomes like designing parts, inserting various base pairs, and providing functional hints for various genes.
Proteins can also be designed using amino acid components, and then their functions in the human body can be simulated. They can even be broken down into individual chemical molecules.
It can also simulate three-dimensional models of various human cells, organs, and the nervous system, and even imitate the interactions between them, perfectly reproducing the operation and structure of the entire human body.
In short, it has all the functions he could think of and couldn't have.
Tang Que couldn't help but click his tongue in amazement.
"Awesome!"
"Since the progress has been greatly ahead of schedule, we can move on to the next step."
"Copied drugs do not need to undergo clinical trials, as long as Animal Experiment show that they are effective."
"The most important thing is to develop our own drugs, so the first issue is the selection of viral vectors."
The construction of gene expression vectors is the most crucial part of genetic engineering. Currently, the most common choices for viral vectors Adenovirus Vector, Slow Virus Vector, and Retrovirus vectors, each with its own advantages and disadvantages.
Slow Virus Vector can integrate into the host genome and effectively infect various cell types, including Neurons, liver cells, Cardiomyocytes, tumor cells, endothelial cells, and stem cells, thereby achieving good Gene Therapy effects.
If patients use Gene Therapy drugs with Slow Virus Vector, the disease-causing gene mutations can be completely modified, thereby curing the disease and turning them into normal people.
However, because the virus integrates into the host's genes, it also raises concerns about its carcinogenicity and genomic safety.
The advantages and disadvantages of Adeno-Associated Virus AAV) are also relatively clear. For example, its genome structure is relatively simple, it has almost no pathogenicity, the threshold for modification and concerns about its use in treatment are easy to overcome, and it is generally believed that it will not integrate into the genome.
These advantages made it the first approved Gene Therapy drug, but its overall load capacity is limited, resulting in fewer functional elements introduced, and in the long term, there is also a slight risk of carcinogenicity.
Retrovirus also integrate into the host genome, but they can only infect dividing cells, and their capacity is limited, making their application relatively narrow.
Therefore, the final choice will be between lentivirus and adenovirus.
"Lentivirus or adenovirus? Lentiviral virus or adenovirus?"
"One is a safe expression, but it cannot completely turn you into a normal person; the other is effective in the long term and can also pass on normal genes."
"It's really hard to make a choice!"
These two thoughts kept echoing in Tang Que's mind. He needed to make a decision and choose the established viral vector in order to continue the next stage of research and development.
"Do you want a permanent solution or just focus on the present?"
"How about we go crazy and choose the most permanent solution?"
"After all, the original intention of Gene Therapy is to help patients return to normal. Hereditary diseases are mainly hereditary. If a short-term approach is chosen, it cannot completely change the patient's life. If they have children, their children will naturally have a very high chance of repeating the same disease."
"It's decided. Since the research and development is progressing so quickly and we've had plenty of extra time, let's start by studying Slow Virus Vector."
"When designing vectors, we need to carefully design the genome, add insulator sequences and regulatory sequences to optimize it, and at the same time improve the packaging plasmids to increase safety."
"First, we need to conduct in-depth simulations in AICell to fully understand all the data before manufacturing samples and using them on animals for experiments. Safety must be the top priority."
"However, if there is indeed a risk of cancer, at least Cancer is treatable and the price is not too high. Compared to the 14 million SMA treatment cost, it is not so hopeless."
"If this route doesn't go smoothly, then we can follow Novartis's lead and continue research on Adenovirus Vector, as long as we use different serum types. I remember Novartis used AVV9, but we can use AVV8 or others."
After making his decision, he buried himself in his work at his desk.
The tasks need to be listed out one by one and assigned to the team.
Then adjustments are made based on different progress.
Fortunately, most of the preliminary work can now be done on the software, which will greatly reduce the workload.
All we need to do then is conduct Cell Experiment to verify it.